Skip to main content

Table 3 Presence of network hubs among the highly ranked genes provided by ProGENI and ProGENI-NH

From: Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance

Treatment Intersection with hubs for ProGENI (p value) Intersection with hubs for ProGENI-NH (p value)
6MP 5 (0.82) 186 (5.75E-269)
6TG 0 (1) 173 (2.10E-235)
Arac 0 (1) 187 (9.61E-272)
Arsenic 4 (0.92) 195 (1.51E-295)
Carboplatin 0 (1) 173 (2.10E-235)
Cddp 4 (0.92) 141 (1.20E-165)
Cladribine 1 (0.99) 195 (1.51E-295)
Docetaxel 3 (0.97) 141 (1.20E-165)
Doxorubicin 12 (0.04) 176 (8.56E-243)
Epirubicin 4 (0.92) 167 (3.82E-221)
Everolimus 8 (0.38) 199 (<1.0E-307)
Fludarabine 0 (1) 197 (3.66E-302)
Gemcitabine 4 (0.92) 176 (8.56E-243)
Hypoxia 38 (3.98E-18) 194 (2.26E-292)
Metformin 5 (0.82) 185 (3.19E-266)
MPA 15 (0.0038) 100 (6.28E-94)
MTX 1 (0.99) 182 (3.54E-258)
NAPQI 2 (0.99) 167 (3.82E-221)
Oxaliplatin 1 (0.99) 163 (5.56E-212)
Paclitaxel 21 (5.30E-06) 175 (2.61E-240)
Radiation 1 (0.99) 199 (<1.0E-307)
Rapamycin 4 (0.916) 192 (3.16E-286)
TCN 2 (0.99) 194 (2.26E-292)
TMZ 4 (0.92) 189 (2.08E-277)
  1. For each treatment, the table shows the size of intersection between the top 500 genes obtained using Robust-ProGENI (or Robust-ProGENI-NH) and the set of 200 genes in the network with the highest degree. P value for the intersection was calculated using a hypergeometric test